Severe fever with thrombocytopenia syndrome virus (SFTSV), also known as the Dabie Banda virus, is an emerging tick-borne Bunyavirus that causes severe fever with thrombocytopenia syndrome (SFTS). Currently, symptomatic treatment and antiviral therapy with ribavirin and favipiravir are used in clinical management. However, their therapeutical efficacy is hardly satisfactory in patients with high viral load. In this study, we explored the antiviral effects of selective estrogen receptor modulators (SERMs) on SFTSV infection and the antiviral mechanisms of a representative SERM, bazedoxifene acetate (BZA). Our data show that SERMs potently inhibited SFTSV-induced cytopathic effect (CPE), the proliferation of infectious viral particles, and viral RNA replication and that BZA effectively protected mice from lethal viral challenge.
regardless of the initial viral load [11]. Favipiravir (T-705) has broad-spectrum anti-RNA virus activity, and both in vivo and in vitro anti-SFTSV activities have been reported [12]. A single-blinded randomized controlled clinical trial was conducted to assess the efficacy and safety of T-705 in treating SFTS [13]. The T-705-treated group showed a shorter interval of viral clearance, lower incidence of hemorrhagic signs, and faster recovery of laboratory abnormalities compared with the controls. Nifedipine, a calcium channel blocker (CCB), inhibited SFTSV replication in vitro and in vivo [14]. Importantly, by performing a retrospective clinical investigation on a large cohort of 2087 patients with SFTS, researchers found that nifedipine administration enhanced viral clearance, improved clinical recovery, and reduced the CFR. However, this study was subject to the limitations that the clinical results of patients with SFTS were retrospective, with no randomization, and potentially flawed. Further clinical investigations of the potential therapeutic effect of CCBs against SFTS should also thoroughly evaluate factors, including the potential drug side effects, drug–drug interactions, and in vivo drug concentration. To date, no licensed vaccines or effective therapeutics have been developed against SFTSV.
No comments:
Post a Comment